Multidrug resistance (MDR) is a major contributory factor in the failure of chemotherapy. Concrete interpretation of P-glycoprotein (P-gp) substrate specificity, whether a substance is a substrate or an inhibitor, represents an important feature of a compound's pharmaceutical profiling in drug design and development. In this work, the P-gp substrate specificity of Maldi 531. + with a potent P-gp substrate such as verapamil was performed. As a result of this combination treatment, two distinct patterns of interaction with P-gp activity were determined by a calcein-acetoxymethyl ester (AM) assay. Depending on the concentratgion, both stimulation and inhibition of MDR activity were observed at certain drug concentrations suggesting biphasic reactions, which can be understood as cooperative stimulation and competitive inhibition, respectively. Verapamil is a strong substrate to P-gp. Substrate specificity of Maldi 531.2 [M+H] + may be less than the substrate specificity of verapamil, but it acts additively together with low concentrations of verapamil in stimulating ATPase activity. On the one hand, verapamil and Maldi 531.2 [M+H] + exerted cooperative stimulation on P-gp. On the other hand, Maldi 531.2 [M+H] + acts as competitive inhibitor at higher concentrations.
Natural products played a highly significant role in the discovery and development of new drugs for the treatment of human diseases [1] . In many parts of the world including the Philippines, the use of natural products is widespread as complementary therapy to various ailments. Thus, an approach to discover potent drugs exploiting the knowledge about the traditional uses of plants has to be developed for new anticancer drugs.
Aglaia has been considered as unique source of natural products with diverse biological activities due to its cyclopenta-[b]tetrahydrobanzoturan skeleton [2] . It includes more than 50 naturally occurring derivatives, which are named after the parent compound, rocaglamide [3] . These compounds were shown to inhibit NF-κB induced gene activation in human T cells and are able to induce apoptosis in drug-resistant cancer cells [2] . Aglain is a structurally related congener isolated from Aglaia spec., which inhibited the growth of human MONO-MAC-6 and MEL-JUSO cancers [4] . Dammarenolic (3,4-secodammarane triterpenoid) acid inhibited HIV-1 infection [5] . The triterpenes roxburghiadiol A and B isolated from Aglaia roxburghiana exerted anti-inflammatory activity and induced mast cell degranulation [6] . Aminopyrrolidinediamides, odorine and odorinol obtained from Aglaia odorata prevented the initiation and promotion steps of carcinogenesis on mouse skin induced by 7,12-dimethylbenz[a]anthracene (DMBA) or nitric oxide derivatives (NO) as initiator compounds and 12-Otetradecanoylphorbol-13-acetate (TPA) as promoter agent [7] . A. odorata was also effective against thymidine kinase-deficient herpes simplex virus type 1 (HSV-1) and phosphonoacetateresistant HSV-1 strains [8] as well as human amoebiasis caused by Entamoeba histolytica [9] . Amide esters which are structurally related to bisamides and flavaglines were isolated from A. tenuicaulis and A. spectabilis [10] . Flavaglines from different plant parts of Aglaia species showed antifungal [11] , insecticidal [10] , antituberculosis and antiviral activities [12] . Two other species of the Meliaceae family, Chukrasia tabularis and A. roxburghiana exerted cytotoxic activity to brine shrimps exhibiting LC 50 values of 1.58 μg/mL and 2.21 μg/mL, respectively [13] . A. edulis collected from Indonesia also revealed cytotoxic activity against cancer cell lines. Silvestrol and episilvestrol from A. foveolata were also effective against tumor cells. Silvestrol contains an 1,4-dioxanyloxy moiety at the C-6 position of the cyclopental[b]benzofuran skeleton. Silvestrol showed anticancer activity in vivo against P388 murine leukemia with a T/C value of 150% 2.5 mg/kg injection. Its activity was selective and independent of the Bcl-2 and p53 status of chronic lymphocytic leukemia cells [14] . Silvestrol isolated from the bark of Aglaia leptantha Miq. collected in Malaysia inhibited the growth of human PC3 prostate xenograft tumors in nude mice in vivo [14] , induced apoptosis in human LNCaP prostate cancer cells through the mitochondrial/ apoptosome pathway without activation of caspase -3 or -7 [15] and human B-cell leukemia by reducing Mcl-1 expression due to inhibition of translation with subsequent mitochondrial damage [16] . In a previous investigation, we reported that the A. loheri active isolate, Maldi 531.2[M+H]+, was cytotoxic towards colon cancer cells as well as drug-sensitive (CCRF-CEM) and multidrug-resistant (MDR) CEM/ADR5000 leukemia cell lines [17] . MDR is a major factor for the failure of chemotherapy in oncology [18] , Resistance is frequently intrinsic to cancer, but after repeated cycles of chemotherapy, even sensitive tumors can acquire drug resistance. A well-known molecular mechanism of MDR is the overexpression of a 170 -180 kDa plasma membrane glycoprotein, P-glycoprotein (P-gp) [19] . It is composed of two homologous regions containing 12 transmembrane domains, six extracellular loops and two cytoplasmic ATP-binding domains [20] . P-gp is encoded by the MDR1 (ABCB1) gene at chromosome 7, q21.1 [21] and transports a wide range of natural compounds and synthetic drugs out of cells [22] . Thereby, P-gp prevents successful tumor treatments using clinically important drugs such as actinomycin D, daunorubicin, doxorubicin, etoposide, mitoxantone, taxol, tenoposide, vinblastine, vincristine and others.
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Given the role of P-gp in MDR of cancer, the pharmacological inhibition of P-gp-mediated efflux has been an attractive experimental treatment concept during the past years [23] . First generation P-gp inhibitors included calcium channel blockers such as verapamil which have the ability to block drug efflux thereby potentiating the cytotoxic effect of anticancer drugs [24] . Other examples are immunosuppressants (e.g. cyclosporine A) and antiestrogens (e.g. tamoxifen and toremifene) [25] . Second generation P-gp inhibitors were clinically non-established, novel compounds with high affinity to P-gp [26] . Third generation P-gp inhibitors blocked P-gp with high specificity to further improve the treatment of MDR tumors. Unfortunately, none of these compounds successfully passed clinical trials and the quest for effective P-gp inhibitors continues.
In the present investigation, we focused on the effect of Maldi 531. 2 [M+H]+ on P-gp activity. Maldi 531.2[M+H]+ is a phenol ester component of A. loheri leaves, which was cytotoxic to both drug-sensitive CCRF-CEM and multidrug-resistant, P-gp overexpressing CEM/ADR5000 leukemia cells with IC 50 values of 0.02 and 0.03 μM, respectively [17] . The present study aimed to address the question, whether this isolate can stimulate or inhibit response of P-gp in MDR leukemia cells. In contrast, CCRF-CEM did not show P-gp ATPase activity, indicating the absence of P-gp expression in plasma membranes of CCRF-CEM (Figure 2 ). In the case of Maldi 531. 2 [M+H] + , a dose dependent increase of P-gp ATPase activity was observed, whose Effect of A. loheri active isolate on the interaction between verapamil and P-gp: To test its effects on MDR activity using whole cells, Maldi 531.2 [M+H] + was combined with verapamil as potent P-gp substrate. Figure 4 shows the effect of Maldi 
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A. loheri in 5.0μM Verapamil Figure 5 , Table 2 ).
In the present work, we evaluated, whether Maldi 531.2 [M+H] + acts as substrate of P-gp using plasma membranes of both CCRF-CEM and CEM/ADR5000 cells. Pi was spectrophotometrically measured in the presence of various concentrations of Maldi 531. We also studied, how Maldi 531.2 [M+H] + interacted with verapamil toward P-gp using intact CEM/ADR5000 cells as targets. To test its effects on MDR activity, we combined Maldi 531.2 [M+H] + with verapamil as potent P-gp substrate. Two distinct patterns of interaction with P-gp activity were determined by calceinacetoxymethyl ester (AM) assay. Calcein-AM is a non-fluorescent, hydrophobic compound that non-specifically enters the cell. Hydrolysis of calcein-AM produces a hydrophilic and strongly fluorescent calcein that is well retained in the cytosol, thus representing an excellent substrate for targeted extrusion by multidrug transporters [27] . The results in this study showed both stimulation and inhibition of MDR activity at different drug concentrations suggesting biphasic reactions, i.e. cooperative stimulation and competitive inhibition [28] , respectively. Verapamil is a strong substrate to P-gp. Substrate specificity of Maldi 531.2 [M+H] + (Figure 3) was less than the substrate specificity of verapamil. Thus, it additively acted with the low verapamil concentration in stimulating ATPase activity. On the one hand, both exerted cooperative stimulation on P-gp (Figure 4) . On the other hand, at higher Maldi 531.2 [M+H] + concentrations at higher concentrations of verapamil, competitive inhibition was observed as it acted as inhibitor ( Figure 5 ). MDR activity was inhibited at higher concentrations of Maldi 531.2 [M+H] + from 24.37% up to 42.98% ( Table 2 ). The reason for the cooperative stimulation and Considering the causative role of P-gp for MDR, its inhibition represents an attractive strategy to improve cancer chemotherapy [29] . Overexpression of P-gp confers resistance practically to all drugs, which are considered as P-gp substrates. P-gp-ATPase activation is associated with the potential H-bond energy of + is supported by structure-activity relationship studies [30] , i.e. "compounds with low H-bond energy have low affinity to P-gp thereby ATPase activity is maximum and slows down with increasing concentration and substrate affinity to the transporter." The authors found that compounds with a high number of hydrogen bond acceptor led to lower ATPase activation or even to a reduction of the basal activity [31] . P-gp activators such as cyclosporine A, vinblastine or vincristine bind with high affinity, but are still extruded out of MDR cells. However, those drugs that do not dissociate from the membrane and are not extruded by P-gp may serve as MDR inhibitors [30] .
The probable interaction of the -OH groups of Maldi 531.2[M+H]
+ with the π electrons of the hydrophobic benzene ring may also give the compound special properties to strongly interact with P-gp making the molecule capable of competitively inhibiting MDR activity at higher concentration levels. The presence of -OH groups makes Maldi 531.2 [M+H] + a potential hydrogen donor, a property observed with most substrates or modulators of P-gp. These -OH groups (H-bond acceptor groups) of Maldi 531.2 [M+H] + are recognized by the hydrogen bond donor groups at the drug interaction sites of the nuclear binding folds (NBF) of P-gp's transmembrane α-helices. According to Seelig [30] , "the bond energy of substrate binding to P-gp is proportional to the number and strength of H-bonds." Therefore, the interaction between Maldi 531.2 [M+H] + and P-gp may be probably determined by the number and strength of H-bonds, a phenomenon that had been difficult to achieve in this study due to the lack of detailed structural elucidation. The evident inhibitory actions of Maldi 531. The desired goal to predict P-gp substrate specificity is actually difficult to obtain due to several circumstances such as differences in substrate specificity values acquired from different assays; lack of understanding about P-gp substrates, modulators and inhibitors; lack of understanding about lipophilicity and amphiphilicity of P-gp substrates; and the difficulty describing the P-gp/ligand relationships, if highly specific binding sites are missing [32] .
The recently reported cytotoxic properties of Maldi 531.2[M+H]
+ [17] and the results of the present investigation were highly encouraging, as Maldi 531.2 [M+H] + showed promising activity against the selected cancer cell lines not only by killing them through dissipation of the mitochondrial membrane potential [17] , but also by competitively inhibiting P-gp ATPase activity which may allow intracellular accumulation of Maldi 531. + may serve as lead compound for novel combination therapies for cancer cells, which are resistant to one drug but remain susceptible to other drugs.
In conclusion, we tested the substrate specificity of a phenolic ester isolate of A. loheri (Maldi 531. + may serve as basis to develop novel combination therapies for cancer cells, which are resistant to one drug but remain susceptible to other drugs. Further investigations are required to validate the mechanism of action of Maldi 531.2 [M+H] + against leukemic and other cells from other tumor types tested.
Experimental
Characterization of the A. loheri isolate: Bioactivity-guided fractionation of a crude extract of A. loheri leaves lead to the isolation of a bioactive comppound, termed Maldi 531.2[M+M]+ [17] . The isolate is a compound that contains aromatic rings ( 6.17-7.9 ppm), a phenolic group ( 4.54 ppm), methoxy groups ( 3.61-3.66 ppm), and several aliphatic chain structures ( 1.87-3.61 ppm). Deducing from the one-dimensional NMR studies, the probable structure of the isolate could be an aromatic (phenolic) ester.
Cell Culture: Human CCRF-CEM leukemic cells and their multidrug-resistant subline CEM/ADR5000 were obtained from Dr. Axel Sauerbrey (Department of Pediatrics, University of Jena, Jena, Germany. Their generation has been described [33] . CEM/ADR5000 cells express P-gp/MDR1/ABCB1 [3] . The cells were maintained in a humidified environment at 37 o C and 5% CO 2 . The cells were grown in RPMI 1640 [-] L-glutamine containing 1% penicillin/streptomycin (10.000 U/mL/10.000 µg/mL) and 10% heat-inactivated fetal bovine serum (FBS) (GIBCO Invitrogen, Germany). Drug resistance of cells was maintained by treatment with 5000 ng/mL doxorubicin hydrochloride (Sigma-Aldrich, Taufkirchen, Germany) once per week.
Substrate specificity test: ATPase assay: This test was performed to investigate, whether Maldi 531.2[M+H]
+ exerts stimulatory or inhibitory effects on P-gp. The hydrolysis of ATP to ADP and P i is used to drive the reactions, where the amount of P i is spectrophotometrically measured and the absorbance is directly proportional to the activity of P-gp. Prepared plasma membrane vesicles from both CCRF-CEM and CEM/ADR5000 cells were utilized in all experiments. Cells numbers of ~1×10 9 were collected from culture and were stored in -80°C until membrane preparation.
Preparation of plasma membranes:
The protocol has been recently published in detail [35] . Frozen cell pellets (~1×10 9 cells) were thawed at 4°C with hypotonic buffer (0.5 mM Tris/HEPES pH 7.4, 0.1 mM EGTA, and 1 μM leupeptin hemisulfate salt solution (Sigma-Aldrich), and then homogenized at 600 rpm before subjecting to 15 min centrifugation at 7,500 rpm. The supernatants were collected and subjected to ultracentrifugation at 35,000 rpm for 30 min. The resulting pellets were resuspended in 0.25 M sucrose buffer containing 10 mM Tris/HEPES, pH 7.4, and 1 μM leupeptin and homogenized again at 600 rpm. The crude membrane fractions were immediately layered over 40% (w/v) sucrose solution before subjecting to another round of ultracentrifugation at 35,000 rpm for 30 min. This time, the centrifuge was set to maximum acceleration but slow deceleration to form a white turbid layer of cell membranes at the interface between the 40% sucrose and 0.25 M sucrose buffer solutions. Then, the white turbid layer of cell membranes was collected by using a glass Pasteur pipette and resuspended in 0.25 M sucrose containing 10 mM Tris-Hepes, pH 7.4, and was centrifuged at 35,000 rpm for 30 min. The supernatants were discarded. The pellets (membrane fractions) were resuspended in 100-200 μL of 0.25 M sucrose containing 10 mM Tris/HEPES, pH 7.4 and collected for protein determination. The protein concentrations were measured using Pierce ® BCA Protein Assay according to manufacturer's instructions (Thermo Scientific, USA). After protein determination, the membrane solutions were stored at -80°C until use.
ATPase Assay: The protocol has been recently published in detail [35] . Reaction mixtures were initially prepared by mixing 10 µL distilled water and 10 µL ATPase buffer as an incubation medium. The ATPase buffer contained 50 mM Tris-Mes (pH 6.8), 2 mM EGTA, 2 mM dithiothreitol, 50 mM potassium chloride, 5 mM sodium azide, and 2 mM ouabain. Subsequently, 10 were sequentially added to the mixtures followed by 1 h incubation at room temperature. The absorbance of each reaction mixture in the 96-well microplates was measured at a wavelength of 655 nm by using Tecan Absorbance Microplate Reader (Tecan, Crailsheim, Germany). The amount of liberated phosphate was quantified by a calibration line established with inorganic phosphate standards. Verapamil was used as positive control and was also tested on CCRF-CEM and water as negative control.
Calcein-AM Assay:
This assay provides information about the interaction between P-gp and the test substance affecting substrate transport. Hence, the potential action of Maldi 531.2 [M+H] + to inhibit or enhance the interaction between the substrate drug (verapamil) and P-gp was evaluated. The protocol of the calceinacetoxymethyl (AM) ester assay has been recently published in detail [36] .
In the present experiments, 300 µL of CEM/ADR5000 cell suspension with a density of 3.×10 6 cells/mL were seeded in a 24-well plate. Eighthundred microliters of test compound were added to the cells in each well. The cells were incubated for 15 min at 37 o C and 5% CO 2 . During incubation, calcein-AM (12 µM) was prepared from 1 mM stock solution (on ice). After incubation, 100 µL of the calcein-AM solution were added to the cells in each well and further incubated for 30 min at 37 o C and 5% CO 2. Subsequently, all samples were transferred to 1.5 mL microfuge tubes (on ice) and centrifugation at 2000 rpm at 4°C for 5 min. The supernatants were discarded, and the cell pellets were resuspended in 700 µL cold RPMI 1640 medium for another round of centrifugation at 2000 rpm at 4 o C for 5 min. Then, supernatants were discarded again. Finally, the cell pellets were resuspended in 700 µL RPMI 1640 medium containing 1 µg/mL propidium iodide (PI). PI was used to double stain dead cells. Cells with DMSO were used as negative control and verapamil, as positive control. 
